Title:
USE OF AVC-29 AS VACCINE ADJUVANT AND VACCINE COMPOSITION CONTAINING ADJUVANT
Document Type and Number:
WIPO Patent Application WO/2023/280303
Kind Code:
A1
Abstract:
The present application relates to a use of AVC-29 as a vaccine adjuvant and a vaccine composition containing said adjuvant. Compared with conventional aluminum adjuvants., AVC-29 has significant advantages in inducing antibody production and cellular immune response. In addition, AVC-29 has good safety, can be applied in many types of vaccine preparations, and is a potentially ideal vaccine adjuvant.
Inventors:
LI SONG (CN)
Application Number:
PCT/CN2022/104620
Publication Date:
January 12, 2023
Filing Date:
July 08, 2022
Export Citation:
Assignee:
UNIV HAINAN (CN)
International Classes:
A61K39/39; A61K39/215; A61P11/00; A61P31/14
Domestic Patent References:
| WO2021130195A1 | 2021-07-01 |
Foreign References:
| CN106459058A | 2017-02-22 | |||
| CN111592602A | 2020-08-28 | |||
| CN111892648A | 2020-11-06 | |||
| CN113476600A | 2021-10-08 |
Other References:
PARTLOW HALEY A, DAVISON CLARA J., LATHROP STEPHANIE K, EVANS JAY T.: "The comparison of two SARS-CoV-2 spike protein antigens in TLR-adjuvanted subunit vaccines.", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 206, no. 1 Suppl., 1 May 2021 (2021-05-01), US , pages 30.06, XP009542556, ISSN: 0022-1767, DOI: 10.4049/jimmunol.206.Supp.30.06
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF: